Overview

A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect each other in the body. Information about any side effects that may occur will also be collected.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Clopidogrel
Phenylethyl Alcohol
Ticlopidine